HPS-4/TIMI 65 ORION-4 will examine the effects of inclisiran, a small interfering RNA (siRNA) that inhibits the synthesis of PCSK9, on cardiovascular outcomes among individuals with atherosclerotic cardiovascular disease. It will be conducted at high-enrolling sites using a streamlined, quality-by-design approach. ORION on ClinicalTrials.gov CONTACT US About ORION PUBLICATIONS HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo-controlled … Continue reading HPS-4/TIMI 65/ORION-4